CoChat

Pharmacogenetics of Warfarin Elimination and its Clinical Implications

Takahashi, Harumi, Echizen, Hirotoshi · 2001 · Clinical Pharmacokinetics

The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.

Abstract

Warfarin is one of the most widely prescribed oral anticoagulants. However, optimal use of the drug has been hampered by its >10-fold interpatient variability in the doses required to attain therapeutic responses. Pharmacogenetic polymorphism of cytochrome P450 (CYP) may be associated with impaired elimination of warfarin and exaggerated anticoagulatory responses to the drug in certain patients. Clinically available warfarin is a racemic mixture of (R)- and (S)-warfarin, and the (S)-enantiomer has 3 to 5 times greater anticoagulation potency than its optical congener. Both enantiomers are eliminated extensively via hepatic metabolism with low clearance relative to hepatic blood flow. CYP2C9 is almost exclusively responsible for the metabolism of the pharmacologically more active (S)-enantiomer. Several human allelic variants of CYP2C9 have been cloned, designated as CYP2C9*1 (reference sequence or wild-type allele), CYP2C9*2, CYP2C9*3 and CYP2C9*4, respectively. The allelic frequencies for these variants differ considerably among different ethnic populations. Caucasians appear to carry the CYP 2C9*2 (8 to 20%) and CYP2C9*3 (6 to 10%) variants more frequently than do Asians (0% and 2 to 5%, respectively). The metabolic activities of the CYP2C9 variants have been investigated in vitro. The catalytic activity of CYP2C9*3 expressed from cDNA was significantly less than that of CYP2C9*1. Human liver microsomes obtained from individuals heterozygous for CYP2C9*3 showed significantly reduced (S)-warfarin 7-hydroxylation as compared with those obtained from individuals genotyped as CYP2C9*1. The influence of the CYP2C9*3 allele on the in vivo pharmacokinetics of (S)-warfarin has been studied in Japanese patients. Patients with the homozygous CYP2C9*3 genotype, as well as those with the heterozygous CYP2C9*1/*3 genotype, had significantly reduced clearance of (S)-warfarin (by 90 and 60%, respectively) compared with those with homozygous CYP2C9*1. The maintenance dosages of warfarin required in Japanese patients with heterozygous and homozygous CYP2C9*3 mutations were significantly lower than those in patients with CYP2C9*1/*1. In addition, 86% of British patients exhibiting adequate therapeutic responses with lower maintenance dosages of warfarin (<1.5 mg/day) had either the CYP2C9*2 or CYP2C9*3 mutation singly or in combination, whereas only 38% of randomly selected patients receiving warfarin carried the corresponding mutations. Furthermore, the former group showed more frequent episodes of major bleeding associated with warfarin therapy. These data indicate that the CYP2C9*3 allele may be associated with retarded elimination of (S)-warfarin and the resulting clinical effects. However, relationships between CYP2C9 genotype, enzyme activity, metabolism of probe substrates, dosage requirements and bleeding complications should be interpreted with caution, and further studies are required.

Overview

Integrity signals

Registry

Crossref · 10.2165/00003088-200140080-00003

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 71 references

Research works printed but not linked: 8

  1. Kunze, 1996, Drug Metab Dispos, 24, 429
  2. Abernethy, 1991, J Pharmacol Exp Ther, 257, 411
  3. Shimada, 1994, J Pharmacol Exp Ther, 270, 414
  4. Schwarz, 2000, Clin Pharmacol Ther, 67, 169
  5. Gaedigk, 2000, Clin Pharmacol Ther, 67, 168
  6. Cascorbi, 1998, Clin Pharmacol Ther, 65, 198
  7. Shintani, 2000, Xenobio Metab Dispos, 15, S307
  8. Stearns, 1995, Drug Metab Dispos, 23, 207

Cited by

See all 312

Metadata

Authors
Takahashi, H., & Echizen, H.
Affiliations
Meiji Pharmaceutical University (JP)
Corresponding author
Takahashi, Harumi
Venue
Clinical Pharmacokinetics
Published
2001
Volume
40
Issue
8
Pages
587-603
ISSN
0312-5963 (ISSN-L)
OpenAlex
W2073073931
Cited by
312
References
71
Citations by year
2026: 1 · 2025: 2 · 2024: 6 · 2023: 4 · 2022: 8 · 2021: 7 · 2020: 8 · 2019: 8 · 2018: 9 · 2017: 10 · 2016: 11 · 2015: 9 · 2014: 11 · 2013: 12 · 2012: 20
FWCI
1.85
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Pharmacokinetics (publishedVersion)
  • PubMed (publishedVersion)
Funders
Japan Research Foundation for Clinical Pharmacology
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Nutrition, Genetics, and Disease
Keywords
warfarin, pharmacogenetics, CYP2C9, cytochrome P450 polymorphisms, S-warfarin, CYP2C9*3, CYP2C9*2, pharmacokinetics, ethnic differences
MeSH terms
Anticoagulants, Aryl Hydrocarbon Hydroxylases, Cytochrome P-450 Enzyme System, Genotype, Half-Life, Humans, Metabolic Clearance Rate, Microsomes, Liver, Pharmacogenetics, Polymorphism, Genetic, Stereoisomerism, Steroid Hydroxylases, Genetic Variation, Warfarin, Area Under Curve, Steroid 16-alpha-Hydroxylase, Cytochrome P-450 CYP2C9

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacogenetics of Warfarin Elimination and its Clinical Implications. https://app.cochat.ai/papers/10.2165/00003088-200140080-00003
The paper
Takahashi, H., & Echizen, H. (2001). Pharmacogenetics of Warfarin Elimination and its Clinical Implications. Clinical Pharmacokinetics. https://doi.org/10.2165/00003088-200140080-00003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.